A string of FDA approvals and late-stage clinical trials has expanded the toolkit for treating seasonal and environmental allergies, giving patients new ways to manage symptoms and, in some cases, retrain their immune systems. Yet every advance so far comes with the same caveat: these therapies reduce allergic reactions without eliminating them. For the tens of millions of Americans who dread pollen season, the gap between “better control” and “cure” remains wide.
Sublingual Tablets Gain Ground, Now Reaching Younger Patients
The FDA has approved four allergen extract sublingual tablets that work by gradually desensitizing the immune system to a specific trigger. GRASTEK targets timothy grass, ORALAIR covers a five-grass pollen mix, RAGWITEK addresses ragweed, and ODACTRA treats house dust mite allergy. Each tablet is placed under the tongue daily over months or years, and each is restricted to one allergen family. That constraint matters: a patient allergic to both grass pollen and dust mites would need separate treatment courses, and no sublingual tablet exists for tree pollen or mold.
The most recent regulatory change came on February 28, 2025, when the FDA expanded Odactra’s label to include children aged 5 to 11 for house dust mite–induced allergic rhinitis, with or without conjunctivitis. Previously, Odactra was only cleared for patients 12 to 65. The expansion opens an option for younger children whose dust mite allergies often worsen indoor symptoms year-round, not just during a defined pollen season. For families wary of injections, a daily tablet that can be taken at home may be more acceptable than allergy shots.
Still, long-term pediatric safety monitoring will depend heavily on post-approval surveillance rather than large new primary trials. That gap is typical for label expansions but leaves unanswered questions about how very young immune systems respond over many years of therapy. Allergists and parents must balance the promise of earlier intervention against the reality that rare adverse events may only emerge in real-world use.
Biologics Raise Tolerance Thresholds but Do Not Erase Risk
Beyond sublingual tablets, injectable biologics are showing that blocking the immune cascade at different points can meaningfully raise the dose of allergen a patient can tolerate before reacting. The Phase 3 OUtMATCH Stage 1 trial, published in The New England Journal of Medicine, tested omalizumab (marketed as Xolair) and found it increased reaction thresholds for several foods. While the trial focused on food allergies rather than pollen, the mechanism is relevant to seasonal sufferers because omalizumab binds immunoglobulin E (IgE), the same antibody class that drives hay fever, asthma flares and many indoor allergies.
The FDA approved omalizumab for food allergy based on NIH-sponsored OUtMATCH data, and the allergy division at NIAID emphasized that the drug reduces risk but does not eliminate it. Patients must still avoid their trigger foods and carry rescue medications. That framing applies equally to seasonal allergy research: a higher tolerance threshold is not immunity. For a ragweed-sensitive patient, for instance, a biologic might prevent hives or wheezing after a short exposure but not protect against weeks of high-pollen counts.
Biologics also bring practical trade-offs. They are expensive, require injections at regular intervals, and can cause side effects ranging from mild injection-site reactions to rare but serious hypersensitivity. For now, their most compelling role in environmental allergy appears to be as adjuncts, supporting immunotherapy or providing a bridge through peak seasons, rather than as standalone cures.
Combining Biologics with Immunotherapy: A Durability Test
One of the more intriguing questions in allergy research is whether pairing a biologic with traditional immunotherapy can produce tolerance that lasts after treatment stops. The CATNIP/ITN057AD trial, a randomized controlled study run through an NIH network, tested exactly that by adding tezepelumab to cat allergen immunotherapy. Results showed stronger improvements in nasal allergen-challenge responses during treatment and, critically, signals of more persistent benefit after discontinuation.
That second finding is what separates this approach from standard symptom relief. Most allergy medications work only while a patient takes them; stop the drug, and the sneezing, itching and congestion return. If a combination strategy can shorten the treatment window while building lasting immune tolerance, it would change the cost-benefit calculation for patients who currently face three to five years of shots or daily tablets.
The CATNIP trial used cat allergen, but the principle could extend to seasonal triggers like grass or ragweed if future studies confirm the durability signal. Researchers are particularly interested in whether early, intensive treatment could “reset” immune responses so that children at high risk for lifelong allergic disease might enjoy years of remission. For now, that remains a hypothesis rather than a clinical recommendation.
New Formulations and Easier Access to Relief
While disease-modifying therapies attract the most research attention, practical access to symptom relief also matters. The RHAPSODY Phase III trial demonstrated that five‑grass sublingual immunotherapy drops are effective and generally well tolerated in adults with grass-pollen allergic rhinoconjunctivitis. Drops represent a distinct formulation from the FDA-approved sublingual tablets and are often compounded or regulated differently in various markets.
No head-to-head trial has compared drops and tablets directly, so clinicians must rely on separate efficacy and safety profiles when advising patients. That absence of comparative data makes it difficult to answer practical questions: Are drops as potent as tablets at similar doses? Do they carry a higher risk of local reactions? Until those studies are done, choices will hinge on availability, regulatory status and patient preference rather than clear superiority of one format.
On the symptom-management side, the FDA approved Astepro Allergy Nasal Spray for over-the-counter sale in June 2021. Astepro contains azelastine, a prescription‑strength intranasal antihistamine that typically acts faster on nasal congestion and sneezing than oral pills. Moving it over the counter removed a doctor-visit barrier and made a potent option available in pharmacy aisles alongside older sprays and tablets.
The shift also changed how patients pay for care. Some people who previously obtained azelastine with insurance coverage now pay retail prices, while others without easy access to clinicians gain a new self-directed option. For health systems, widespread OTC use raises familiar concerns about underdiagnosed asthma, chronic sinus disease or nonallergic rhinitis being masked by symptom relief rather than properly evaluated.
Professional guidelines, including the Rhinitis 2020 practice parameter update, already place intranasal antihistamines and steroids among first-line therapies for moderate to severe symptoms and caution against prolonged use of topical decongestant sprays that can cause rebound congestion. In that context, easier access to intranasal antihistamines fits a broader push to steer patients toward safer long-term options, provided pharmacists and clinicians reinforce correct use.
The Persistent Gap Between Control and Cure
Taken together, these advances sketch a more nuanced landscape for people living with seasonal and environmental allergies. Sublingual tablets and drops offer targeted desensitization for specific pollens and dust mites, but they are limited by allergen scope and the need for long treatment courses. Biologics such as omalizumab and tezepelumab can raise reaction thresholds and may, in combination with immunotherapy, nudge the immune system toward more durable tolerance, yet they come with high costs, injection schedules and lingering uncertainty about how long benefits last.
Meanwhile, over-the-counter access to agents like azelastine improves day-to-day symptom control but does not change the underlying disease. For many patients, the practical reality remains a layered strategy: avoidance where possible, fast-acting nasal sprays or antihistamines for flares, and, for those who can commit the time and resources, immunotherapy or biologic-based regimens that promise deeper but still incomplete protection.
The research trajectory points toward more personalized combinations, matching the right biologic, route of immunotherapy and duration of treatment to each patient’s allergen profile and risk tolerance. Until then, the message from current evidence is both encouraging and sobering: modern therapies can dramatically blunt seasonal misery and reduce the danger of severe reactions, but they stop short of a cure. For now, “less allergic” is the realistic goal, and closing the remaining gap will require long-term studies that track not just symptom scores, but true, lasting immune change.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
